Spyre reports preliminary $741M cash; suspends ATM offering

Spyre Therapeutics, Inc.

Preliminary cash, equivalents and marketable securities of $741M as of March 31, 2026.
Includes $30M legacy asset disposition proceeds; $23M expected to be paid to CVR holders in Q2 2026.
Effective April 13, 2026, terminated ATM prospectus; no further share sales under Sales Agreement until new filing.
Sales Agreement with TD Securities remains in force; company funded without current need for dilution.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.